Genentech’s Hopes For Keeping Tecentriq Breast Cancer Claim May Rest With Trial In Early Disease Recurrence

 
• By Sue Sutter
  
Breast cancer cell
Tecentriq's accelerated approval in triple-negative breast cancer is on the line. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers